CCM
CRSP icon

Chilton Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Chilton Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-20
Closed -$1K – 291
2022
Q2 		$1K Buy
+20
New +$1.18K ﹤0.01% 601
2022
Q1 		– Sell
-20
Closed -$2K – 300
2021
Q4 		$2K Buy
+20
New +$1.75K ﹤0.01% 603

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Chilton Capital Management's CRSP Position: Q3 2022 in Review

Chilton Capital Management sold out of CRISPR Therapeutics (CRSP) in Q3 2022, closing a stake of 20 shares — an estimated $1K sold.

Chilton Capital Management first reported a position in CRSP in Q4 2021 and held it in 2 quarters. The position peaked at $2K in Q4 2021. 436 funds tracked by Wall St. Rank hold CRSP as of Q3 2022.

  • Chilton Capital Management reported no remaining CRISPR Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Chilton Capital Management sold 20 CRISPR Therapeutics shares in Q3 2022, an estimated $1K.
  • Chilton Capital Management first reported a position in CRISPR Therapeutics in Q4 2021 and held it in 2 quarters.
  • Chilton Capital Management's CRISPR Therapeutics position peaked at $2K in Q4 2021.
  • 436 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2022.

Based on Chilton Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.